Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a report issued on Monday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals stock opened at $0.93 on Monday. Navidea Biopharmaceuticals has a twelve month low of $0.72 and a twelve month high of $2.19. The company’s 50 day moving average is $0.87. The company has a market cap of $28.23 million, a P/E ratio of -2.38 and a beta of 1.40.

Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) last released its earnings results on Wednesday, March 23rd. The company reported ($0.12) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative net margin of 2,209.23% and a negative return on equity of 517.32%. The company had revenue of $0.05 million for the quarter.

Navidea Biopharmaceuticals Company Profile (Get Rating)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Featured Articles

• Get a free copy of the StockNews.com research report on Navidea Biopharmaceuticals (NAVB)
• MarketBeat: Week in Review 5/30 – 6/3
• Dividend Capture Strategy: What You Need to Know
• Okta On Verge Of Multi-Week Rally
• Don’t Bet On A Bounce For RH 
• Xiaomi Co: Facing Macro Headwinds

Want More Great Investing Ideas?